Oct 2026· Asia-Pacific Journal of Clinical Oncology· 0 citations· 13 references
Medicine
TL;DR
This narrative review synthesizes contemporary evidence and proposes a practical four-layer algorithm in which clinical urgency, tissue and biomarker readiness, and precision opportunities are assessed in parallel to preserve treatment opportunities.
Abstract
Cancer of unknown primary (CUP) is a heterogeneous group of metastatic malignancies in which the primary site remains unidentified despite appropriate diagnostic evaluation. Historically, most patients with unfavorable CUP have received empirical platinum-based chemotherapy, but recent advances in immune checkpoint inhibition, comprehensive genomic profiling (CGP), tissue-agnostic therapy, and tissue-of-origin prediction are changing the treatment landscape. Contemporary management therefore requires integration rather than simple replacement of empirical therapy. Randomized evidence from CUPISCO supports early CGP with subsequent molecularly guided treatment after disease control with platinum-based induction, while CUP-specific immunotherapy studies and Japanese real-world data demonstrate clinically meaningful activity in selected patients. Conversely, randomized tissue-of-origin-directed trials have produced mixed results, underscoring the need to distinguish diagnostic prediction from proven therapeutic benefit. Major guidelines broadly agree on purposeful diagnostic evaluation, recognition of favorable subsets, and individualized management, but differ in the timing and emphasis placed on molecular testing and tissue-of-origin assays. These differences are particularly relevant in the Asia-Pacific region, where access, reimbursement, turnaround time, and treatment availability vary substantially. This narrative review synthesizes contemporary evidence and proposes a practical four-layer algorithm in which clinical urgency, tissue and biomarker readiness, and precision opportunities are assessed in parallel. The central principle is that clinically indicated therapy should not be delayed solely while awaiting molecular results; instead, empirical treatment and biomarker planning should be coordinated to preserve treatment opportunities.
The increasing adoption of targeted therapies over chemotherapy has made randomized controlled trials (RCT) with chemotherapy increasingly challenging in advanced NSCLC with actionable genomic alterations (AGA), particularly for rare subgroups. Contemporary chemotherapy outcomes specific to AGAs are lacking despite gro...
D. Zhou, Sarah J. Lord, F. Lin et al.· Lung· 0 citations
Advanced lung adenocarcinoma has historically been associated with poor survival and substantial treatment-related morbidity, reflecting limited diagnostic precision and non-selective therapeutic strategies. This case-based review traces the evolution of management through three eras using a representative presentation...
Mayah Cousens, Ahmed Al-Janabi, Nooralhuda Alshami et al.· UCC Student Medical Journal· 0 citations
Bevacizumab is an important component of first-line therapy for advanced epithelial ovarian cancer; however, the precise identification of patients who will benefit and how to optimize its use in the era of poly (ADP-ribose) polymerase inhibitors (PARPi) remains a core challenge in clinical practice. This review system...
Lan Zhong, Liang Song· Frontiers in Pharmacology· 0 citations
This review has synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL and examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL.
This focused narrative review examines how biomarkers can distinguish established treatment eligibility from investigational strategies intended to address immune exclusion and resistance in triple-negative breast cancer.
Jing-Na Wu· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.